Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

House Democrats Set To Move Bill After Accord With Blue Dogs, Liberals Objecting
House Democrats on Wednesday made a deal with fiscally conservative Blue Dog Democrats on a health reform bill that "would reduce the overall cost of the package and ensure more funding for rural hospitals, concessions that could allow the Energy and Commerce Committee to finish its consideration of the legislation," The Washington Post reports. The deal will be considered on the House floor no earlier than September, according to several lawmakers. House lawmakers plan to conclude their markup of the legislation in the Energy Committee Thursday.
generic viagra online
FDA Approves Expanded Use Of HIV Drug
Merck announced on Thursday that the FDA has approved expanded use of its HIV drug, Isentress, Reuters reports (Pierson, 7/9). Isentress has been FDA-approved since 2007, but was limited "to use in patients who had drug-resistant strains or were failing on other therapies, also in combination with other HIV drugs. Now it can be used in all adult patients," the AP/CNBC.com reports. According to AP/CNBC.com, "Isentress is an integrase inhibitor, meaning it works by blocking the enzyme integrase, one of three types of enzymes the AIDS virus uses to reproduce and infect cells" (7/9).
News of the day
The Necessity Of Adrenalectomy At The Time Of Radical Nephrectomy: A Systematic Review
UroToday.com - To take the adrenal or not at the time of radical nephrectomy, that is the question. These researchers from New York University School of Medicine performed an extensive literature search to determine the role of adrenalectomy at radical nephrectomy and discovered that the incidence of solitary, synchronous, ipsilateral adrenal involvement, and therefore potentially curable tumor disease with ipsilateral adrenalectomy occurred extremely infrequently - in only 1% to 5% of cases.
Endocrinology

NovImmune Successfully Completes NI-0801 Phase I Clinical Study

NovImmune, an immunology-focused biotech company dedicated to the development of therapeutic monoclonal antibodies, announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, doubleblinded, placebo controlled, single centre, phase I study of escalating single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01) demonstrated that NI-0801 is well tolerated at doses up to and including 20mg/kg. Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection. IP-10 is constitutively expressed at low levels in thymic, splenic and lymph node stroma tissues, but its expression can be induced on a variety of cell types including endothelial cells, keratinocytes, fibroblasts, monocytes and neutrophils. IP-10 not only mediates leukocyte recruitment, but also drives T-cell proliferation upon antigenic stimulation. Cell migration in response to chemoattractants requires the retention of IP-10, which is also true for all other chemokines, in the vicinity of the site of inflammation to make sure cells are recruited where they are needed. IP-10 expression at sites of inflammation, leads to local accumulation of specialized cells responsible for the inflammation process in a number of different autoimmune conditions including psoriasis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, atherosclerosis, liver fibrosis and sarcoidosis. Dr Penelope Ward, Chief Medical Officer commented that "since increased IP-10 (CXCL10) levels correlate with disease severity, an ability to neutralize its effects with a target specific monoclonal antibody offers a promising strategy for the treatment of diseases such as liver fibrosis and lupus, for which therapeutic options are currently limited." NI-0801 is well aligned within NovImmune"s overall expertise and strategy in the field of chemokines to develop potential future therapeutics. Along these lines NovImmune is very happy to have become a member of the European F6 consortium "Innovative Chemokine-based Therapeutic Strategies for Autoimmunity and Chronic Inflammation" (INNOCHEM). Dr Marie Kosco-Vilbois, CSO at NovImmune, commented that "it is a great pleasure and opportunity for NovImmune to be part of a European group of Excellence in the field of future therapeutic applications of the "chemiome", where eminent academic and industrial partners cooperate to translate chemokine biology into effective therapeutics." NovImmune SA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009